DISHMAN

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange vide letter dated August 7, 2013 a copy of Disclosure under Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Janmejay R Vyas has submitted to the Exchange, vide letter dated August 05, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2013.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the disclosure of voting result as per clause 35A of the Listing Agreement of the Annual General Meeting (AGM) of the members of the Company held on July 30, 2013.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that Mr. Mark Griffiths, who is CEO of Carbogen Amcis AG., Switzerland, has been appointed as CEO of Dishman Group of Companies, world wide.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that Mr. Mark Griffiths, who is CEO of Carbogen Amcis AG., Switzerland, has been appointed as CEO of Dishman Group of Companies, world wide.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board of Directors at its meeting held on May 28, 2013 has taken the following the decison : (1) The Board has approved the appointment of whole time Director Mr. Arpit J. Vyas as a Managing Director of the Company with effect from May 28, 2013 and since his present term expires on May 31, 2014, also approved his re-appointment as a Managing Director of the Company for a further period of five years w.e.f. June 01, 2014, subject to approval of the members at their ensuing Annual General Meeting scheduled to be hel

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from July 20, 2013 to July 30, 2013 (both days inclusive) for the purpose of determining the entitlement of Final Dividend as recommended as well as for holding the Annual General Meeting on July 30, 2013.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 28, 2013, among others, the following decisions were taken : 1) For the year 2012-13, the Board has recommended the final dividend @ 60% (i.e. Rs. 1.20 per equity share of Rs. 2.00 each) on the paid-up equity share capital of the Company.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated April 03, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated March 13, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated March 05, 2013 a copy of Disclosure in terms of Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated March 04, 2013 a copy of Disclosure in terms of Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated March 02, 2013 a copy of Disclosure in terms of Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated Februay 28, 2013 a copy of Disclosure in terms of Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated Februay 27, 2013 a copy of Disclosure in terms of Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange, vide letter dated Februay 19, 2013 a copy of Disclosure in terms of Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange vide letter dated Februay 11, 2013 a copy of Disclosure in terms of Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2012.

Janmejay R Vyas has submitted to the Exchange vide letter dated January 25, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange vide letter dated December 31, 2012, a copy of Disclosure under Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Janmejay R. Vyas has submitted to the Exchange vide letter dated December 05, 2012, a copy of Disclosure of release of encumbered shares as required under Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2012.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the Voting Results of the Annual General Meeting of the members of the Company held on September 25, 2012 as per Clause 35A of the Listing Agreement.

Janmejay R. Vyas has submitted to the Exchange vide letter dated September 05, 2012, a copy of Disclosure of release of encumbered shares as required under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 15, 2012 to September 25, 2012 (both days inclusive) for the purpose of determining the entitlement of Final Dividend as well as for Annual General Meeting to be held on September 25, 2012.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 31, 2012, has recommended the final dividend @ 60% (i.e. Rs. 1.20 per equity share of Rs. 2.00 each) on the paid up equity share capital of the Company. The final dividend, if declared by the members at the AGM, will be paid on or after September 28, 2012.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2012.

Janmejay R. Vyas has submitted to the Exchange vide letter dated May 16, 2012, a copy of Disclosure in terms of Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Mr Janmejay R Vyas has submitted to the Exchange vide letter dated March 30 2012, a copy of Disclosure in terms of Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2011.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Company's Wholly Owned Subsidiary company, namely Carbogen Amcis AG., Switzerland has acquired Creapharm Parenterals, a subsidiary of France based Creapharm Group.Creapharm Parenterals is a contract development and manufacturing organization specializing in liquid, semi-solid and injectable aseptic dosage forms. As part of this acquisition, Creapharm Parenterals has changed its name to CARBOGEN AMCIS SAS.The acquisition will extend CARBOGEN AMCIS' comprehensive range of development and manufacturing services by adding

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2011.

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange the Disclosures under Regulation 7(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that company's Wholly Owned Subsidiary company, namely Carbogen Amcis AG., Switzerland has successfully completed US FDA PAI for a new hi potency drug for a US multinational.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on July 29, 2011.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company, at their meeting held on May 26, 2011, has decided and resolved to convene and hold the Annual General Meeting of the Members of the Company on July 29, 2011 and the Register of Members & Share Transfer Books of the Company will remain closed from July 16, 2011 to July 29, 2011 (both days inclusive) for determining the entitlement of Final Dividend as recommended as well as for holding the Annual General Meeting on July 29, 2011.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 26, 2011, has recommended payment of dividend @ 60% on the paid up equity share capital of Rs. 16,13,94,272/- (i.e. Rs. 1.20 per equity share of Rs. 2/- each) for the Financial year 2010-11, subject to approval of members in the ensuing Annual General Meeting.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has decided to publish Audited Financial Results for the accounting year ended March 31, 2011 within the stipulated period of 60 (sixty) days (i.e. on or before May 30, 2011) from the end of the financial year 2010-2011. Thus, the unaudited financial results for the last quarter of the accounting year ended March 31, 2011 will not be published.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange a copy of Disclosure under Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Annual General Meeting (AGM) of the Members/Shareholders of the Company held on July 30, 2010 members have approved and passed, among others, the following resolutions: (i) The Audited Annual Accounts of the Company together with necessary annexures and reports for the financial year 2009-2010, ended on March 31, 2010, were approved and adopted.(ii) In respect of the Financial year 2009-2010, a dividend @ 60% (Rs.1.20 Per share) on the paid up equity shares of the company has been declared by the members. Furth

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has, on June 16, 2010, made allotment of 750 (Seven Hundred and Fifty only) Secured Redeemable Non Convertible Debentures (NCDs) of the face value of Rs.10.00 Lacs (Rupees Ten Lacs only) each, in forms of Separately Transferable Redeemable Principal Parts (STRPPS) of having the face value of Rs.1.00 lakh (Rupee One lakh only) each, aggregating Rs.75.00 Crores (Rupees Seventy Five Crores only).

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange statement of appropriations as per Clause 20 of the listing agreement.